Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:37:24.113Z.
Calculation as of: 2026-10-06T16:37:24.113Z.
Quote observation: 2026-10-06T16:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$669.14M
PS Ratio
7.27
TTM Avg
3326.30
3Y Avg
4783.92
5Y Avg
2925.64
Market Cap
$690.15M
PS Ratio
307.83
TTM Avg
191.08
3Y Avg
130.74
5Y Avg
130.74
Market Cap
$707.01M
PS Ratio
11983.17
TTM Avg
4690.70
3Y Avg
1617.75
5Y Avg
973.20
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $674.70M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $677.49M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.41M | 1.89 | 1.93 | 2.72 | 2.45 |
| Solid Biosciences Inc. (SLDB)vs › | $684.21M | N/A | 7.55 | 21.50 | 21.50 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $669.14M | 7.27 | 3326.30 | 4783.92 | 2925.64 |
| Anteris Technologies Global Corp. (AVR)vs › | $690.15M | 307.83 | 191.08 | 130.74 | 130.74 |
| OmniAb, Inc. (OABI)vs › | $653.83M | 17.01 | 10.67 | 12.29 | 15.93 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $707.01M | 11983.17 | 4690.70 | 1617.75 | 973.20 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $708.40M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $710.13M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q3 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q4 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2027Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
